Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which has completed phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Corxel Pharmaceuticals to develop and commercialize etripamil. Milestone Pharmaceuticals Inc.was incorporated in 2003 and is headquartered in Montreal, Canada. Show more

Location: 1111 Dr. Frederik-Philips Boulevard, Montreal, QC, H4M 2X6, Canada | Website: https://www.milestonepharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

73.78M

52 Wk Range

$0.63 - $2.75

Previous Close

$1.38

Open

$1.42

Volume

3,744,773

Day Range

$1.42 - $1.50

Enterprise Value

128.4M

Cash

55.96M

Avg Qtr Burn

-8.467M

Insider Ownership

4.71%

Institutional Own.

22.25%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.